basalinsuliner

Basalinsuliner, or basal insulin analogs, are long-acting insulins designed to provide a relatively constant background level of insulin to cover the body's basal needs in people with diabetes. They are used to control fasting glucose and are often a component of basal-bolus regimens or as monotherapy in type 2 diabetes inadequately controlled with oral agents.

Pharmacology and examples: These insulins have a slow onset and a prolonged, flat action profile, reducing peaks and day-to-day variability compared with intermediate-acting insulins. Common examples include insulin glargine (available in U-100 and U-300 formulations), insulin detemir, and insulin degludec. Their duration ranges from about 20-24 hours for some analogs to more than 42 hours for degludec, allowing once-daily dosing for many patients.

Indications and use: Basalinsuliner are indicated for type 1 diabetes as part of a basal-bolus regimen and for type 2 diabetes requiring insulin therapy. They are typically combined with rapid-acting insulins at meals to cover prandial glucose excursions. Dosing is individualized based on fasting glucose, body weight, activity, and other factors, with adjustments to minimize hypoglycemia.

Safety and administration: They are given by subcutaneous injection, usually once daily but sometimes twice daily depending on the formulation and patient needs. Rotating injection sites helps prevent lipohypertrophy. Hypoglycemia is the main risk; other adverse effects include weight gain and, rarely, allergic reactions. Dosing may require modification during illness, stress, or changes in kidney or liver function.

History and terminology: The development of basal insulins aimed to provide steadier, longer-acting background insulin with less hypoglycemia than older formulations such as NPH. The term basalinsuliner is common in several European languages to describe these long-acting analogs.